Inclusion criteria

          -  histologically or cytologically confirmed, stage IV or recurrent NSCLC that carries a
             ROS1 rearrangement, as per anchored multiplex PCR

          -  ECOG performance status of 0 to 2

          -  Male or female≥ 20 years of age

          -  treatment naive or may be allowed up to 2 prior systemic anti-cancer therapy for their
             stage IV or recurrent NSCLC, which includes cytotoxic chemotherapy and I-O, but
             excludes crizotinib.

          -  measurable lesion (using RECIST 1.1 criteria)

          -  measurable lesion (using RECIST 1.1 criteria)

          -  archival tissue sample available, collected either at the time of diagnosis of NSCLC
             or any time since

          -  Subjects who meet the following criteria:

               -  ANC 1.5 x 109/L -Platelet 100 x 109/L

               -  creatinine 1.5 x ULN

               -  AST (SGOT) and ALT (SGPT) 3 x ULN (If there is Liver Metastasis 5 x ULN

               -  Total bilirubin 1.5 x ULN

          -  written informed consent prior to any study specific procedures

          -  Leptomeningeal carcinomatosis may be included

        Exclusion criteria

          -  More than two actionable mutations

          -  Patients who received prior crizotinib therapy

          -  Any major operation or irradiation within 4 weeks of baseline disease assessment

          -  Any clinically significant gastrointestinal abnormalities which may impair intake or
             absorption of the study drug

          -  Subjects with symptomatic central nervous system (CNS) metastases who are
             neurologically unstable or who have CNS complications that require urgent
             neurosurgical intervention(e.g. resection or shunt placement)

          -  Other co-existing malignancies or malignancies diagnosed within the last 3 years with
             the exception of basal cell carcinoma or cervical cancer in situ or treated thyroid
             cancer.

          -  Subjects with an uncontrolled major cardiovascular disease (including AMI within 12
             months, unstable angina within 6 months, over NYHA class III congestive heart failure,
             congenital long QT syndrome, 2° or more AV Block and uncontrolled hypertension)

          -  Pregnant or lactating female

          -  Patients with known history of extensive disseminated bilateral interstitial fibrosis
             or interstitial lung disease, including a history of pneumonitis, hypersensitivity
             pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically
             significant radiation pneumonitis (i.e. affecting activities of daily living or
             requiring therapeutic intervention).

          -  Receiving medications that meet one of the following criteria and that cannot be
             discontinued at least 1 week prior to the start of treatment with LDK378 and for the
             duration of participation (see Appendix 1 Tables):

          -  Medication with a known risk of prolonging the QT interval or inducing Torsades de
             Pointes (please refer to http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm)

          -  Strong inhibitors or strong inducers of CYP3A4/5 (please refer to
             http://medicine.iupui.edu/flockhart/table.htm or http://www.druginteractioninfo.org)

          -  Medications with a low therapeutic index that are primarily metabolized by CYP3A4/5,
             CYP2C8 and/or CYP2C9 (please refer to http://medicine.iupui.edu/flockhart/table.htm or
             http://www.druginteractioninfo.org)

          -  Therapeutic doses of warfarin sodium (Coumadin) or any other coumadin-derived
             anti-coagulant. Anticoagulants not derived from warfarin are allowed (eg, dabigatran,
             rivaroxaban, apixaban).

          -  Unstable or increasing doses of corticosteroids

          -  enzyme-inducing anticonvulsive agents

          -  herbal supplements

          -  Patients who have received thoracic radiotherapy to lung fields ≤ 4 weeks prior to
             starting the study treatment or patients who have not recovered from
             radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy
             to thoracic vertebrae and ribs), radiotherapy ≤ 2 weeks prior to starting the study
             treatment or patients who have not recovered from radiotherapy-related toxicities.
             Palliative radiotherapy for bone lesions ≤ 2 weeks prior to starting study treatment
             is allowed.